blincyto
amgen europe b.v. - blinatumomab - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
zegomib 3,5 mg
egis pharmaceuticals plc, maďarsko - bortezomib - 44 - cytostatica
zegomib 1 mg
egis pharmaceuticals plc, maďarsko - bortezomib - 44 - cytostatica
azacitidín ever pharma 25 mg/ml prášok na injekčnú suspenziu
ever valinject gmbh, rakúsko - azacitidín - 44 - cytostatica
azacitidine zentiva
zentiva k.s., Česká republika - azacitidín - 44 - cytostatica
palonosetron accord
accord healthcare s.l.u. - palonosetron - vomiting; nausea; cancer - antiemetics a antinauseants, - palonosetron dohode je indikovaný u dospelých na:prevencia akútnej nevoľnosti a zvracanie spojené s vysoko emetogenic rakoviny je chemoterapia,prevenciu nevoľnosti a zvracanie spojené s mierne emetogenic rakoviny je chemoterapia. palonosetron dohoda je uvedené v pediatrických pacientov 1 mesiaca veku a staršie:prevencia akútnej nevoľnosti a zvracanie spojené s vysoko emetogenic rakoviny je chemoterapia a prevenciu nevoľnosti a zvracanie spojené s mierne emetogenic rakoviny je chemoterapia.
palonosetron hospira
pfizer europe ma eeig - palonosetron hydrochlorid - nausea; vomiting; cancer - antiemetics a antinauseants, - palonosetron hospira je indikovaný u dospelých na:prevencia akútnej nevoľnosti a zvracanie spojené s vysoko emetogenic rakoviny chemoterapiou;predchádzanie nevoľnosti a zvracanie spojené s mierne emetogenic rakoviny je chemoterapia. palonosetron hospira je uvedené v pediatrických pacientov 1 mesiaca veku a staršie:prevencia akútnej nevoľnosti a zvracanie spojené s vysoko emetogenic rakoviny je chemoterapia a prevenciu nevoľnosti a zvracanie spojené s mierne emetogenic rakoviny je chemoterapia.
palonosetron fresenius kabi 250 mikrogramov injekčný roztok
fresenius kabi s.r.o., Česká republika - palonosetrón - 20 - antiemetica, antivertiginosa
ferant 250 mikrogramov injekčný roztok
medochemie ltd., cyprus - palonosetrón - 20 - antiemetica, antivertiginosa
calcium folinate sandoz 10 mg/ml
sandoz pharmaceuticals d.d., slovinsko - kalciumfolinát - 19 - antidota, detoxicantia